Animal models are established, important tools for preclinical safety and efficacy testing. Companies are advancing more “humanized” models to better reflect human responses, while at the same time ...

New data presented at EACR 2026 highlighted anti-tumor activity, improved safety characteristics, and pharmacokinetic ...

Many drugs still fail after promising preclinical results, raising difficult questions about how disease is modelled in the ...

The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s applications ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...

The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and ...

Researchers have demonstrated a promising new approach to stopping pancreatic cancer before it starts, using experimental drugs to eliminate microscopic precancerous lesions in the pancreas.

HkeyBio announced today the launch of preclinical disease model platforms covering Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and IgA Nephropathy (IgAN). This platform integrates s ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Key opportunities in the global preclinical CRO market include increased outsourcing by biopharma companies to reduce costs and access expertise, especially in developing markets like India and China ...